Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Equity Ratio (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Equity Ratio for 16 consecutive years, with 0.35 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 540.55% year-over-year to 0.35, compared with a TTM value of 0.35 through Dec 2025, up 540.55%, and an annual FY2025 reading of 0.36, up 116.79% over the prior year.
  • Equity Ratio was 0.35 for Q4 2025 at Arrowhead Pharmaceuticals, down from 0.36 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.64 in Q1 2022 and bottomed at 0.06 in Q4 2024.
  • Average Equity Ratio over 5 years is 0.45, with a median of 0.46 recorded in 2022.
  • The sharpest move saw Equity Ratio plummeted 80.06% in 2024, then surged 540.55% in 2025.
  • Year by year, Equity Ratio stood at 0.58 in 2021, then dropped by 23.8% to 0.44 in 2022, then plummeted by 37.62% to 0.28 in 2023, then tumbled by 80.06% to 0.06 in 2024, then soared by 540.55% to 0.35 in 2025.
  • Business Quant data shows Equity Ratio for ARWR at 0.35 in Q4 2025, 0.36 in Q3 2025, and 0.38 in Q2 2025.